Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SON-DP is a transcription factor (TF) protein drug with potential antineoplastic activity, currently in Phase I clinical trials for the treatment of advanced and metastatic solid tumors, including breast, ovarian, pancreatic, and colorectal cancers. Upon administration, SON-DP induces pluripotent reprogramming in cancer cells to generate transient induced pluripotent stem cells (tiPSCs), which then rapidly re-differentiate into normal tissue cells. This mechanism aims to convert malignant tumor cells back into non-cancerous tissue in situ. The drug is administered intravenously and is based on protein-induced in-situ cell reprogramming technology. Qurgen developed this agent as part of its pipeline of transcription factor drugs targeting various diseases[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SON-DP.